Boston, United States
doDOC, a dynamic component of the Envision Pharma Group, empowers teams to streamline the creation and review of scientific documents. It offers a unique real-time collaborative editing platform, aiming to enhance productivity by allowing document processes to be completed 70% faster. The solution's core strengths lie in its advanced features, such as granular permission controls, exhaustive action traceability, task automation, and seamless integrations, making it a preferred choice for enterprise clients, especially in the pharmaceutical and biotechnology sectors.
Established in 2015, doDOC operates out of the United States, playing a critical role in the Analytics, Enterprise Software, Information Technology, and SaaS industries. Its potential was recognized with a $1.50M seed round investment from Palm Drive Capital in November 2020. The platform already collaborates with 19 out of the top 20 pharmaceutical giants, showcasing its extensive reach and capability to meet complex industry requirements.
